Consequently, as therapy progresses, some fractions of MM clones may evade the benefits of treatment by either downregulating the expression of CD138 or gradually reducing its presence in the cell membrane, eventually leading to treatment failure and disease progression in some patients. This evidence concerns the gene SDC1 and Miyoshi myopathy.